BTMD Q2 2026 Earnings Call Summary

1Key Financial Results and Metrics

Revenue: Decreased by 9.5% to $44.2 million.

Procedure Revenue: Declined 13.9% to $30.3 million, impacted by a $3.3 million loss due to a voluntary product recall.

Dietary Supplements Revenue: Grew 5.7% to $11.4 million, driven by e-commerce growth.

Gross Margin: Fell to 65.4% from 71.6%, primarily due to recall-related costs and increased reliance on high-cost third-party pellets.

SG&A Expenses: Increased to $32.4 million from $24.2 million, largely due to higher legal expenses.

Net Loss: Reported at $7.4 million, compared to a net income of $3.9 million in Q2 2025.

Adjusted EBITDA: Decreased to $5.6 million with a margin of 12.6%.

Cash Position: Cash and cash equivalents improved to $11.2 million from $5.3 million at the end of Q1 2026.

2Strategic Updates and Business Highlights

The company has made significant internal improvements, focusing on corporate culture, operational alignment, and commercial team enhancement.

Asteria Health has restored inventory levels and is operating at normalized production, which is expected to improve profitability in the second half of the year.

The strategic roadmap emphasizes operational improvements, clinic retention, and enhancing practitioner experience.

BioT is exploring inorganic growth opportunities while prioritizing organic growth.

3Forward Guidance and Outlook

Procedure revenue is expected to improve sequentially in Q3 and Q4 2026, although year-over-year growth will remain negative due to earlier disruptions.

Dietary supplements revenue is projected to grow at a mid-to-high single-digit rate for the year.

Revised full-year revenue guidance is now above $175 million (down from $190 million) and adjusted EBITDA above $25 million (down from $38 million).

4Bad News, Challenges, or Points of Concern

The company faced headwinds from a voluntary product recall, which affected procedure volume and clinic attrition.

Clinic attrition remains elevated at around 8%, with no significant changes in competitive pressures noted.

New clinics have been slower to ramp up productivity due to the sales team's focus on recall-impacted clinics.

5Notable Q&A Insights

Management expressed confidence in improving procedure revenue in the second half, citing restored supply and accountability in sales efforts.

Discussions around inorganic growth opportunities highlighted a desire to expand reach and enhance practitioner engagement.

Legal expenses are expected to decrease in the latter part of the year following the resolution of several outstanding legal matters, which should normalize SG&A expenses moving forward. Overall, while BTMD is navigating challenges from a product recall and declining procedure revenue, the company is optimistic about operational improvements and future growth potential.